Allogene Therapeutics
ALLO
192 hedge funds and large institutions have $1.15B invested in Allogene Therapeutics in 2022 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 65 increasing their positions, 49 reducing their positions, and 12 closing their positions.
267% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 12
33% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 49
19% more funds holding
Funds holding: 161 → 192 (+31)
19% more call options, than puts
Call options by funds: $1.99M | Put options by funds: $1.67M
3.71% more ownership
Funds ownership: 70.2% → 73.91% (+3.7%)
0% less capital invested
Capital invested by funds: $1.15B → $1.15B (-$1.8M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$13.9M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$13.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$11M |
| 4 |
Two Sigma Investments
New York
|
+$9.16M |
| 5 |
Millennium Management
New York
|
+$8.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$18.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$16.9M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$7.38M |
| 4 |
JP Morgan Chase
New York
|
-$7.3M |
| 5 |
Morgan Stanley
New York
|
-$7.08M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
JWA
201
JFS Wealth Advisors
Hermitage,
Pennsylvania
| – | +$149 | +11 | New |
|
|
AF
202
Allworth Financial
Folsom,
California
| – | +$503 | +37 | New |
|
203
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$544 | +40 | New |
|
ALLO Hedge Fund Activity: Q3 2022 in Review
192 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q3 2022, worth a combined $1.15B — down 0.16% from $1.15B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new ALLO positions and 12 closed out — a net gain of 32 holders — while 65 added to existing stakes and 49 trimmed.
The largest buyer was State Street, adding an estimated $13.9M. The largest seller was Woodline Partners, cutting an estimated $18.1M.
- 192 institutional investors held Allogene Therapeutics (ALLO) as of Q3 2022, up from 161 in Q2 2022.
- Funds reported $1.15B of Allogene Therapeutics stock for Q3 2022, down 0.16% quarter-over-quarter.
- 44 funds opened new Allogene Therapeutics positions in Q3 2022 and 12 closed out, a net change of +32 holders.
- The largest Allogene Therapeutics buyer in Q3 2022 was State Street, an estimated $13.9M added.
- The largest Allogene Therapeutics seller in Q3 2022 was Woodline Partners, an estimated $18.1M sold.
Based on aggregated 13F filings for Q3 2022.